Management Team

Dr Michael Thormann, CEO & CSO

Michael Thormann is co-founder and co-inventor of MOREsystem® and MolMind®. He leads the technology platform development, implementation, and its application throughout the drug discovery and development process. As CSO, he is responsible for the success of the cross-functional, highly interdisciplinary team and empowers scientific excellence and technological leadership, and industrial applicability. Prior Origenis, as Head of Molecular Modeling at Morphochem, he invented protein- and ligand-based drug design methods, QSPR, parallel evolutionary search algorithms, and multiparametric optimization techniques, that together with Cippix® and BRAINstorm® have lead to Origenis’ proprietary AI Innovation Platform. He received his Ph.D. in biochemistry from the University of Leipzig in 1998. He worked in the field of secondary structure design and conformational analysis of special non-natural peptides and held several post-doctoral positions at the University of Barcelona and Polytechnical University of Catalonia.

Andreas Treml helms and oversees business operations, HR and manages budget and financial goals. As co-founder of Origenis he is contributing biological expertise to the management team.  In prior positions he was responsible for assay development and integrating ‘New Technologies’ for parallel biological characterization. Andreas holds a Ph.D. in biology and worked in the field of steroid hormone receptors and transcription factors for therapeutic oncology and across multiple therapeutic target areas during industrial and academic collaborations.

Dr Gergana Galabova,
VP Translational Medicine

Gergana Galabova is responsible for the pre-clinical research and development and the translation of R&D results from the Origenis Technology Platform into therapeutic areas with unmet medical needs. Gergana graduated Veterinary Medicine at Trakia University, holds Doctoral Degree from Vet Med Uni Vienna, with focus animal histology and histopathology and has six years post-doctoral experience, with focus on the in vivo and in vitro deciphering of the MAPK Kinase Pathway from the Max F. Perutz Laboratories, University of Vienna. Gergana is a former employee and Head of the Neurodegeneration Department of AFFIRIS AG, Vienna. She has more than 10 years’ experience in the field of vaccine pre-clinical and clinical research and development and has successfully translated several pre-clinical therapeutic and biomarker programs into clinical settings and clinical endpoints. Gergana joined Origenis in 2018 as VP Translational Medicine.

Dr Roland Köstler, Director Chemistry

Roland Köstler leads the chemistry team at Origenis. He is responsible for the design of novel compound classes, the development of their synthetic routes and involved in the IP protection. Additionally, he coordinates the external CMC activities. Roland holds a Ph.D. from the LMU Munich in Chemistry. He joined Origenis in 2008, and has more than 20 years’ experience in synthetic chemistry in many fields of medicinal chemistry, with the major focus on kinase inhibitors.